Patents by Inventor Stefan Zahn
Stefan Zahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170073421Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: ApplicationFiled: November 2, 2016Publication date: March 16, 2017Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
-
Patent number: 9376496Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.Type: GrantFiled: July 31, 2015Date of Patent: June 28, 2016Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
-
Publication number: 20160046712Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: March 23, 2015Publication date: February 18, 2016Inventors: Søren Berg Padkær, Peter Andreas, Nicolai, Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20160024215Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.Type: ApplicationFiled: July 31, 2015Publication date: January 28, 2016Inventors: Petrus Johannes Louis SPEE, Peter Andreas Nicolai Reumert WAGTMANN, Stefan ZAHN, Elisabeth D. GALSGAARD, Birgitte FRIEDRICHSEN, Véronique BRAUD
-
Publication number: 20150344576Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: August 18, 2015Publication date: December 3, 2015Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 9127052Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.Type: GrantFiled: June 28, 2011Date of Patent: September 8, 2015Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
-
Publication number: 20150191547Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: March 16, 2015Publication date: July 9, 2015Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Patent number: 9018366Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 18, 2013Date of Patent: April 28, 2015Assignees: Innate Pharma S.A.S, Novo Nordisk A/SInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 8981065Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: July 8, 2013Date of Patent: March 17, 2015Assignees: Novo Nordisk A/S—Novo Alle, Innate Pharma S.A.S., University of GenoaInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Louis Spee, Michael Wilken
-
Publication number: 20150044231Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: ApplicationFiled: August 25, 2014Publication date: February 12, 2015Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
-
Patent number: 8614307Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: January 11, 2012Date of Patent: December 24, 2013Assignees: Novo-Nordisk A/S—Novo Alle, Innate Pharma S.A.S.Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurant Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkjaer, Kristian Kjaergaard, Petrus Johannes Loius Spee, Milchael Wilken
-
Publication number: 20130295116Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: ApplicationFiled: June 18, 2013Publication date: November 7, 2013Inventors: Stefan Zahn, Louise Hjerrild Zeuthen, Anker Jon Hansen, Kristian Kjaergaard, Soeren Lund
-
Publication number: 20130287770Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: July 8, 2013Publication date: October 31, 2013Inventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagne, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thorolfsson, Soren Berg Padkaer, Kristian Kjaergaard, Pieter Johannes Loius Spee, Milchael Wilken
-
Publication number: 20130164299Abstract: The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.Type: ApplicationFiled: June 28, 2011Publication date: June 27, 2013Applicant: C.N.R.S.Inventors: Petrus Johannes Louis Spee, Peter Andreas Nicolai Reumert Wagtmann, Stefan Zahn, Elisabeth D. Galsgaard, Birgitte Friedrichsen, Véronique Braud
-
Patent number: 8388970Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: October 2, 2008Date of Patent: March 5, 2013Assignees: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20130004514Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: ApplicationFiled: June 6, 2012Publication date: January 3, 2013Applicant: Novo Nordisk A/SInventors: Stefan Zahn, Louise Hjerrild Zeuthen, Anker Jon Hansen, Kristian Kjaergaard, Soeren Lund
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8222376Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 6, 2006Date of Patent: July 17, 2012Assignees: Novo Nordisk A/S, Inmate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard
-
Patent number: D759292Type: GrantFiled: April 23, 2015Date of Patent: June 14, 2016Inventor: Karl Stefan Zahn
-
Patent number: D760421Type: GrantFiled: April 10, 2015Date of Patent: June 28, 2016Inventor: Karl Stefan Zahn